EYEPOINT INC

Eyepoint Pharmaceuticals (NASDAQ:EYPT) shows steady trading at $0.41, analysts hold mixed views, and the company’s ocular drug‑delivery focus fuels cautious investor interest.

Eyepoint Pharma’s share rises 4.88% as analysts eye the upcoming DME study; downgrades reflect earnings miss but institutional confidence remains.

Eyepoint’s stock crashes after a failed Phase 3 trial, analyst downgrades, and legal scrutiny – is the DME program enough for a turnaround?